Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Arizona

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risks

For decades, public health communication has centered on broad wellness principles, emphasizing preventive care and the management of common conditions through widely prescribed medications. Within this legacy framework, general health information often highlighted the benefits of treatments for chronic diseases, such as osteoporosis, without delving into the nuanced risks associated with long-term pharmaceutical use. This foundational approach served to educate populations on maintaining bone density and overall health, relying on established medical guidelines and patient awareness campaigns. As the understanding of medication side effects evolved, a critical shift occurred from general health promotion to a more focused examination of specific adverse outcomes linked to drug exposure. In the context of mass production and widespread prescription of bisphosphonates like Fosamax, a particular concern emerged regarding osteonecrosis of the jaw—a condition where bone tissue in the jaw fails to heal after minor trauma, such as tooth extraction. This transition from a general health context to a targeted occupational exposure concern is especially relevant for individuals who have been prescribed Fosamax over extended periods, as the risk of jaw complications becomes a tangible issue requiring legal and medical attention. The pivot now centers on understanding how prolonged pharmaceutical exposure, rather than general health maintenance, necessitates careful monitoring and, in some cases, legal recourse to address potential harm.

Understanding Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate use, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The incidence of ONJ is rare, and atypical femoral fracture is uncommon, based on available data (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Legal Considerations for Arizona Patients

For patients in Arizona who have developed ONJ after taking Fosamax, legal considerations regarding the statute of limitations are relevant. The statute of limitations for product liability claims in Arizona generally requires filing within two years from the date the injury is discovered or should have been discovered with reasonable diligence. This timeline is critical for affected patients seeking legal recourse. The adequacy of warnings regarding Fosamax and ONJ is a key factor in such cases. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the warning also states that in placebo-controlled clinical studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may be relevant in evaluating whether the warnings were adequate to inform patients and healthcare providers of the risk. The timeline between exposure to Fosamax and documented harm from ONJ can vary. Symptoms may appear within days to months after starting the drug, but ONJ can also develop after longer periods of use, especially with continued exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This variability in onset can complicate the determination of when the statute of limitations begins to run, as it may depend on when the patient discovered or should have discovered the connection between Fosamax and their injury. Attorney-related considerations for affected patients include the need to gather medical records documenting the diagnosis of ONJ, evidence of Fosamax use, and any dental procedures or other risk factors. Patients should also be aware that the statute of limitations may be affected by the date of diagnosis or the date when the injury was reasonably discoverable. Consulting with a legal professional experienced in pharmaceutical litigation is advisable to assess individual circumstances and ensure timely filing. In summary, Fosamax is associated with a rare risk of ONJ, with onset varying from days to months after starting the drug. The risk may increase with longer use and is influenced by factors such as dental procedures and comorbidities. For Arizona patients, the statute of limitations for filing a claim is typically two years from discovery of the injury, making prompt legal evaluation important.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax claims in Arizona?

In Arizona, the statute of limitations for product liability claims, including those related to Fosamax and osteonecrosis of the jaw, is generally two years from the date the injury is discovered or should have been discovered with reasonable diligence. It is important to consult with an attorney promptly to ensure your claim is filed within this timeframe.

What are the risk factors for osteonecrosis of the jaw from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.